- Eye & Lip Serum
- Facial Youth Accelerator Serum
- Anti-Aging Spot Serum
- Body Gel Wash
- Body Hydrator & Moisturizer
- Sun Protection Body Crème
- Sun Protection Facial Crème
- Facial Reparative Enzyme Crème
- Facial Cleanser
- Hydrating Toner
- Reparative Youth Serum
- Scar Normalizer
- Anti-Cellulite
- Anti-Acne
- Facial Youth Rejuvenation

- Facial Skin Care
- Signature Facial Skin Care
- Clinical Facial Skin Care
- Medical Microdermabrasion
- Therapeutic Massages
- Signature Therapeutic Massages
- Signature Body Procedures
- Clinical Body Procedures
- Waxing Procedures
- Full Day at the Spa
- Half Day at the Spa

Jacques D.Barth, M.D., Ph.D., FACC

CURRICULUM VITAE

Southern California Prevention and Research Center (SPARC) Inc.

Executive Director/Director of Research

Education:

Fellowships:

Professional Appointments:

Languages:     Fluent: English, Dutch, German, French  Limited: Spanish, Italian

Honors and Awards:

Licensure:

Cardiovascular Diseases of all Member States the European Union (Re-certification as of June 10, 1999 for 5 additional years)

Academic Appointments:

Specific Teaching Responsibilities:

• Mentor during cardiology fellowship program (Erasmus Medical School, Rotterdam, Netherlands)
• Teaching during medical school training:  School of Nursing on "Pathophysiology of Human Disease" (Erasmus Medical School, Rotterdam The Netherlands)
• Cardiovascular educational program for primary care physicians (University of Nijmegen, Netherlands)
• Tutorials on coronary heart disease at different European/American/Canadian and South American Cardiological institutes
• Tutorials at the first, second, and third symposium on management of atherosclerosis, The Netherlands
• Postdoctoral education in preventive-cardiology leading a thesis 1991, University of British Columbia, Vancouver, Canada (collaboration with University of Gottingen, Germany) on Preventive Cardiology
• PhD thesis mentor and examiner in cardio/lipid-biochemistry leading to a thesis:  on liposomes 1991, University of British Colombia, Vancouver, BC
• Teaching cardiology fellows at LAC County Hospital in echocardiography reading and trans-esophageal echocardiography techniques
• Teaching a postdoctoral course at the Institute of Prevention Research (USC) on the pathophysiology of disease 1995-1996

 Specific Administrative Responsibilities:

• Pharmacotherapy Advisory Committee at the University of Nijmegen, The Netherlands
• Chair, Networking Committee Canadian Heart and Stroke Foundation, Health Heart Coalition
• Core Member British Columbia Heart and Stroke Foundation, Vancouver, BC
• Cardiology Representative on behalf of the Netherlands Cardiological Society on Cholesterol
• Member Scientific/Grants Committee Liproprotein Section Netherlands Heart Foundation
• Cardiological Consultant to the Netherlands National Health Care Program 'STG 2000' (Stuurgroep Toekomstscenario's Gezondheidzorg).  Task Force Netherlands National Health Care 2000
• Chair, Roundtable Conference:  'Cholesterol Consensus: A Transatlantic Perspective', October 31-November 1, 1991, Amsterdam, The Netherlands 

Society Memberships;

• Southern California Lipoprotein Working Group
• Los Angeles County Medical Association
• Member of California Medical Association
• California Society for Cardiac Rehabilitation and Prevention
• Los Angeles Society for Echocardiography
• Royal Dutch Society of Medicine
• Dutch Association of Specialists in Internal Medicine
• Dutch Society of Cardiology
• International Federation of Societies in Cardiology
• European Society of Cardiology
• American Society for Cardiac and Pulmonary Rehabilitation
• American Society for Clinical Research
• New York Academy of Sciences
• American Heart Association, Council on Arteriosclerosis
• American Heart Association, Council on Epidemiology and Prevention
• American Heart Association, Council on Stroke
• British Columbia Medical Association
• British Columbia Cardiological Society
• Canadian Cardiac Rehabilitation Society
• American Society of Preventive Cardiology
• American Medical Association

Consultantship:

• Nederlands Tijdschrift voor Cardiologie (Netherlands Journal of  Cardiology) expertise: Preventive Cardiology
• Principal Investigator, Osteoporosis Medical Center/SPARC on Cardiovascular Studies, Beverly Hills, California
• DIA consultant on cardiovascular surrogate endpoints May 1, 1999, Philadelphia
• University of California Berkeley, Special Division on Smoking in Ethnic Minorities
• Cardiovascular Consultant to Medical Data Management, Hologic, Bedford, MA
• Cardiovascular Consultant Parexel Imaging, Parexel Inc., Waltham, MA

Research Activity:

Previous European experience (partial listing) with Bayer AG (Nifedipine, The Intact Study), Bristol Myers-Squibb Inc (Pravastatin, The REGRESS study), Pfizer (doxazosin, the DAPHNE study),Kaneka, Merck, Bristol Myers Squibb, Leo Pharma, Farma Schwartz, Ciba-Geigy, Sandoz, Astra AB, Unilever NV, BASF A.G. (KNOLL), 3M, Lorex (Synthelabo), Hoechst, Genentech, Upjohn.

Major area of Research Interest:

Biomedical Image Processing of Non-invasive Ultrasound Techniques Preventive Cardiovascular and Cerebrovascular Medicine

Behavioral Modification of Risk Factors for Cardiovascular and Cerebrovascular Disease.

CORE Laboratory Supervisor Image Processing  Prevention Concepts Inc.

Consultant to the Osteoporosis Medical Center Beverly Hills on Tobacco for the State of California Tobacco Tax Initiative.

SPARC Research Center Inc., Encino, California, executive Director/Director of Research

Bibliography:

Peer reviewed:

1.         Juttmann JR, Barth JD, Birkenhäger JC. Treatment of anticonvulsant osteomalacia with 1  alpha hydroxycholecalciferol. Br Med J, 1977;1:551.

2.         Barth JD, Bakker WH, Hennemann G. Discrepancies between Iodine and Technetium thyroid scintigraphy. JAMA, 1978;240:463‑464.

3.         Krenning EP, Barth JD, Bakker WH, Hennemann G. The Unifocal Node in the Thyroid. Ned Tijdschr Geneesk, 1981;125:1092‑1093 (Dutch)

4.         Barth JD, Jansen H, Hugenholtz PG, Birkenhäger JC. Postheparin lipases, lipids and related hormones in men undergoing coronary arteriography to assess atherosclerosis. Atherosclerosis 1983;48:235‑241.

5.         Barth JD, Meester GT, Lubsen J. Cardiovasculaire risicofactoren bij mannen (49 jaar of jonger), een jaar na het eerste myocardinfarct. (Coronary risk factors in young male surivors (under 49 years of age) one year after a first myocardial infarction.) Ned Tijdschr Geneesk 1985;129:1378‑1381 (Dutch).

6.         Arntzenius AC, Kromhout D, Barth JD, Reiber JHC, Bruschke AVG, Buis B, Gent CM van, Kempen‑Voogd N, Strikwerda S, Velde EA van der. Diet, Lipoproteins and the progression of coronary atherosclerosis: The Leiden Intervention Trial. N Engl J Med 1985;312:805‑811.

7.         Kromhout D, Arntzenius AC, Kempen-Voogd N, Kempen HJ, Barth JD, Voort van der HA, Velde van der EA. Long-term effects of a linoleic acid-enriched diet, changes in body weight and alcohol consumption in serum total and HDL-cholesterol. Atherosclerosis 1987;66:99-105.

8.         Barth JD, Jansen H, Arntzenius AC, Reiber JHC, Kromhout D, Birkenhäger JC. Progression and Regression of human coronary atherosclerosis. The role of lipoproteins, lipases and thyroid hormones in coronary lesion growth. Atherosclerosis 1987;68:51-58.

9.         Barth JD, Blankenhorn DH, Wickham E, Lai JY, Chin HP, Selzer RH. Quantitative ultrasound pulsation study in human carotid artery disease. Arteriosclerosis 1988;8:778-781.

10.       Arntzenius AC, Barth JD. High Density Lipoproteins and regression of atherosclerosis. Neth J Cardiol 1991;4:41-45.

11.        Pijls NHJ, Uijen GJH, Pijnenburg T, Leeuwen K. van, Aengevaeren WRM, Barth JD, Arend J. den, Hoevelaken A, Van der Werf T. Reproducibility of mean transit time for maximal myocardial flow assessment by videodensitometry. Int J Cardiac Imag 1991;6:101-108.

14.       Barth JD, Arntzenius AC. Progression and regression of atherosclerosis, what roles for LDL-cholesterol and HDL-cholesterol: a perspective. Eur H J 1991;12:952-957.

15.       Kramers C, de Mulder PHM, Barth JD, Wagener DJT. Acute right ventricle heart failure in a patient with renal cell carcinoma after interferon therapy. Neth J Med 1993;42:65-68.

16.        Barth JD, Zonjee MMB, The REGRESS Research Group. Regression growth evaluation statin study (REGRESS): Study Design and baseline characteristics in 600 patients. Can J Cardiol 1992;8: 925-932.

17.        Betteridge DJ, Barth JD. Summary of Cholesterol Consensus: a Trans-Atlantic Perspective. Int J Cardiol 1992;37:S3-S11.

18.        Barth JD, Betteridge DJ. Introduction to Cholesterol Consensus: a Trans-Atlantic Perspective. Int J Cardiol 1992;37: S1-S2.

19.       Blankenhorn DH, Selzer RH, Crawford DW, Barth JD, Liu Chao-ran, Liu Ci-hua, Mack WJ, Alaupovic P. Beneficial effects of colestipol-niacin therapy on carotid atherosclerosis: two and four year reduction of intima-media thickness measured by ultrasound. Circulation 1993;88:20-29.

20.       Barth JD. Pixel or death: Experience from clinical trials assessing lipid lowering therapy. Canadian J Cardiol 1995;26:5-11(C)

21.       Elliott T, Barth JD, Mancini GBJ. Vitamin E on endothelial function in men after myocardial infarction. Am J Cardiol 1995;76:1188-90.

22.       Sanchez, A, Barth JD, Zhang L. Teenage diet and its relationship to the risk of atherosclerosis among teenagers. Am J Clin Nutr 2000 (in press).

Other Manuscripts:

1.         Barth JD. Impressions of the 54th Scientific Session of the American Heart Association. Hart en Vaten 1982;9:11‑13 (Dutch).

2.         Barth JD, Meester GT. A patient with angina pectoris and hypercholesterolemia. Hart Bulletin 1983;14:87‑90 (Dutch).

3.         Barth JD. Impressions of the First European Meeting On Hypertension: Milan, May 29 ‑ June 3, 1983. Hart en Vaten 1983;10:7‑8 (Dutch).

4.         Barth JD. Lipid Research Clinics Coronary Primary Prevention Trial, editorial. Hart en Vaten 1984;4:1‑3 (Dutch).

5.         Barth JD. Impressions 56th Scientific Meeting American Heart Association. Hart en Vaten 1984;2:1‑3 (Dutch).

6.         Barth JD. Twee jonge patienten met recentelijk ontstane klachten van vermoeidheid.(Two young patients with recently developed complaints of tiredness). Hart Bulletin 1985;16:111‑114 (Dutch).

7.         Arntzenius AC, Kromhout D, Barth JD, Reiber JHC, Bruschke AVG, Buis B, van Gent CM, Kempen‑Voogd N, Strikwerda S, van der Velde EA. Diet, lipoproteins and the progression of coronary atherosclerosis: The Leiden Intervention Trial. Hart Bulletin 1985;16:131‑134 (Dutch).

8.         Barth JD. Twee jonge mannen met klachten van pijn op de borst en kortademigheid.(Two young men with angina and progressive dyspnea). Hart en Vaten 1986;13:7‑9 (Dutch).

9.         Barth JD, Arntzenius AC. Regression of Human Atherosclerosis: An update on clinical, Angiographical and Pathological Aspects. Rev. Argentina Card. 1986;54:152‑155 (Spanish).

10.       Barth JD. Een jongeman met heftige pijn op de borst, (A young man with severe chest pain).  Hart Bulletin 1986;17:194‑195,198.(Dutch).

11.       Barth JD, Jansen H, Arntzenius AC, Reiber JHC, Kromhout D, Birkenhger JC. Diet and the role of lipoproteins, lipases and thyroid hormones in coronary lesion growth. J Cardiovas Pharmac 1987;10 (Suppl 9):S42-S46.

12.       Barth JD. A Cardiologist in California (1) Hart en Vaten 1987:14:9‑10 (Dutch)

13.       Barth JD. A Cardiologist in California (2) Hart en Vaten 1987;14:17-18 (Dutch).

14.       Barth JD. Role of diet in atherosclerosis. Medische Spiegel 1987;1:42 (Dutch).

15.       Barth JD. Pathofysiologische achtergronden van de behandeling van lipidenstoornissen. (Pathophysiological aspects of lipoprotein disorders therapy) Hart Bull 1988;142-148 (Dutch).

16.       Barth JD, Holwerda NJ, Klomps HC, Mulder PGH. Diltiazem of metoprolol als eerste keuze bij stabiele angina pectoris (het DIANE-onderzoek). (Diltiazem or metoprolol as initial drug of choice in stable angina pectoris). Ned Tijdschr Cardiol 1988;2:7-17 (Dutch).

17.       Barth JD. Secondary prevention after myocardial infarction: Focus on beta-adrenergic blocking agents and calcium channel blockers. Ned Tijdschr Cardiol 1988;2:47-51 (Dutch).

18.       Barth JD. A Cardiologist in California (3). Hart en Vaten 1988;15:14-16 (Dutch).

19.       Barth JD. A Cardiologist in California (4): The Biomedical Image Processing Laboratory (I). Hart en Vaten 1988;15:21-25.

20.       Jansen H, Laird-Meeter K, Baggen MGA, Barth JD, van Es GA, Lubsen J, Birkenhäger JC. A comparative study on the effects of prazosin and propranolol treatment on plasma lipoproteins and post-heparin plasma lipase activities in male patients after coronary bypass grafting. 1988.Proceedings Georgetown University conference 1123-1126

21.       Barth JD. A Cardiologist in California (5), Biomedical Image Processing Laboratory (II). Hart en Vaten 1988;15:10-14.

22.       Berg B. and Barth JD. Voorziet een cholesteroltest in een behoefte ? (What is the use for cholesterol testing ?) Cordiaal 1989;4:117-120 (Dutch).

23.       Barth JD. Coronary Artery Disease: progression criteria. Am Heart J. 1989;118:1356.

24.       Barth JD, Arntzenius AC. Regression of atherosclerosis in humans: the evidence and the role of changes in cholesterol and HDL-cholesterol. In Proceedings of the Second International Symposium on the Management of Atherosclerosis, Rotterdam The Netherlands 1989. eds. J.D.Barth, J.C. Birkenhäger and A.C. Arntzenius pp:27-52.

25.       Barth JD. Highlights of the Second International Symposium on the management of atherosclerosis. J Drug Res 1989;14:1-2.

26.       Barth JD. Cardiac failure: past, present and future. Cardiac Care 1989;1:1-7 (Dutch).

27.       Barth JD. Effecten van matig alcohol gebruik (Effects of moderate alcohol use) Medisch Contact 1989;2 16-17 (Dutch).

28.       Barth JD. Twee interessante en controversiele satelliet symposia tijdens het 11th Congress of the European Society of Cardiology (Two interesting and controversial satellite symposia during the 11th Congress of the ESC). Ned Tijdsch Cardiol 1989;3:360-363 (Dutch).

29.       Barth JD. Een patient met recidiverende "gele" huidknobbels. (A patient with repeated yellow skin eruptions) Hart en Vaten 1989;2:16-17

30.       BarthJD, Kruisbrink OAE, Van Eijk AL.Inhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolaemia. Br Med J 1990;301: 669.

31.       Montauban van Swijndrecht AD, Meyer R, Barth JD, Ackerstaff RGA. Ultrageluid als weegschaal voor atherosclerose. (Ultrasound measurement as parameter for atherosclerosis assessment) Vakblad v Non-Invasieve Vaatdiagnostiek 1990;3:9-11 (Dutch).

32.       Barth JD. Interventie studies inzake hypertensie (Intervention Studies on Hypertension).Medicus 1990;8:Nr 253,4-5 (Dutch).

33.       Barth JD. Amiloride of triamtereen:voor-en nadelen van 2 kortwerkende, frequent gebruikte kaliumsparende diuretica. (Amiloride or triamterene: advantages and disadvantages of 2 frequently used short acting potassium saving diuretics) Modern Medicine 1990;14:220-227 (Dutch).

34.       Barth JD. Regressie van atherosclerose: een strijd waarbij het goede over het kwade prevaleert? (Regression of atherosclerosis: a battle in which only good prevails ?) Modern Medicine 1990;12: 821-825 (Dutch).

35.       Barth JD. Differential pharmacological and clinical findings of cholesterol synthesis inhibitors. Proc. New perspectives on the treatment of hypercholesterolaemia and atherosclerosis. Amsterdam, Netherlands pp 7-11 (October 5, 1990).

36.       Barth JD. Clinical experience in the Netherlands with amlodipine (Norvasc) in exertional angina. Proc. Calcium-antagonists: rationale for 24-hour action. Sandwich, U.K. pp.1-3 ( June 15, 1990).

37.       Barth JD. Nutrition and regression of human atherosclerosis. Proc. 4eme Symposium de Creteil sur Nutrition, Lipides et Lipoproteines. Creteil, France. pp 1-4 (May 11, 1990).

38.       Barth JD. Regression of human coronary atherosclerosis: what is the mechanism? In Prospects and Strategies in cardiovascular research II eds: Nollin de S., Janssen J. 1990 pp.3 Assen/Maastricht: van Gorkum Publ. ISBN 902322535X 

39.       Bernink PJLM, Weerd P de, Cate FJ ten, Remme WJ, Barth J, Enthoven R, Haagen FDM, Holwerda NJ, Klomps HC and coinvestigators. An 8-Week Double-Blind Study of Amlodipine and Diltiazem in Patients with Stable Exertional Angina Pectoris. J Cardiovascular Pharm 1991;17 (Suppl 1):S53-S56.

40.       Barth JD. Practical management of lipids in coronary heart disease. Neth J Cardiol 1991;4:83-86.

41.       Eijk AL van, Kruisbrink OAE, Barth JD. Voedselconsumptie bij medicamenteuze behandeling van familiaire hypercholesterolemie.(Macronutrients intake during lipid lowering drug therapy in familial hypercholesterolemia) Ned Tijds v Dietisten 1991;46:10-13 (Dutch).

42.       Kastelein JJP, Barth JD, Arntzenius AC. High-density lipoprotein. Hart Bulletin 1992;23:14-18.

43.       Barth JD. Preventiecardiologie. Ned Tijdschr Cardiol. 1992;6:281-282.

44.       Barth JD. Should regression of atherosclerosis be induced? Proceedings of symposium 'Atherosclerosis: diagnosis, treatment and prevention', Amsterdam, May 8, 1992:83-93.

45.       Barth JD. European perspective. Int J Cardiol 1992;37:S14.

46.       Barth JD, Mancini GBJ. Is Cardiovascular Disease Reversible ? J CME 1993; June:19-24.

47.       Barth JD. Clinical comparison of the bile acid sequestrant colestipol and the HMG-CoA reductase inhibitor simvastatin in Familial Hyperlipidemia- Another Perspective. Today's Therapeutic Trends 1993;11:1-15.

48.       Barth JD. Nutritional Intervention: An approach to treatment of coronary artery Disease. Can Lipid Rev 1993;3:8-14.

49.       Barth JD, Mancini GBJ. Update 1995:Drug intervention in Atherosclerosis. Current Opinion in Lipidology. 1995:6:1-5.

50.       Barth JD. Assessment of possibilities to detect change of atherosclerosis in Proceedings of the Third International Symposium on the Management of Atherosclerosis. ISBN 90-9005582-7 Vianen, the Netherlands. p 51-54.

51.       Barth JD. Cholesterol Lowering in the Elderly. Canadian J Clin Pharmacol 1995; 1:32-33.

Abstracts:

1.         Barth JD, Jansen H, Hugenholtz PG, Reiber JHC, Birkenhäger JC. Testosterone, Estradiol 17 ß and Post heparinic lipases in atherosclerotic heart disease. Proceedings 6th International Symposium on Atherosclerosis. Schettler FG, Gotto AM, Middelhoff G, Habernicht AJR, Jurutka KR. Editors. Springer Verlag Berlin, 1982;A118.

2.         Barth JD, Jansen H, Hugenholtz PG, Birkenhäger JC. Liver lipase activity, HDL‑Cholesterol and related hormones in male patients with no or severe atherosclerosis assessed by coronary angiograms. Arteriosclerosis 1981;1:(5)A375.

3.         Barth JD, Jansen H, Reiber JHC, Birkenhäger JC, Hugenholtz PG. HDL‑Cholesterol, postheparin lipases in male patients with coronary artery disease. Clin Res 1982;30:A171.

4.         Meltzer RS, Roelandt J, Barth JD. M‑Mode contrast-echocardiography can yield similar velocity information to Doppler Echocardiography. Clin Res 1982;30:A205.

5.         Arntzenius AC, Strikwerda S, Kempen N, Bruschke AVG, Reiber JHC, Barth JD, Gent CM van, Houtsmuller UMT, Buis B. Coronary lesions and serum lipids before and after diet in 22 patients. Circulation 1982;66:(II) A284.

6.         Arntzenius AC, Kromhout D, Kempen N, Velde EA van der, Houtsmuller UMT, Gent CM van, Reiber JHC, Barth JD, Strikwerda S. Effect of diet on total cholesterol/HDL‑C ratio in patients of the Leiden Regression Trial. Circulation 1983;68:(III) A904.

7.         Arntzenius AC, Strikwerda S, Bruschke AVG, Reiber JHC, Barth JD, Velde EA van der, Gent CM van, Houtsmuller UMT, Kempen‑Voogd N, Wezel LA, Kromhout D, Buis B. The Leiden Intervention Trial: Coronary lesion and S‑lipids  before and after two years dietary intervention in 30 patients. Proceedings 5th International Meeting on Atherosclerosis and Cardiovascular Diseases, Bologna, 1983, November 28‑30.

8.         Barth JD, Reiber JHC, Hugenholtz PG, Birkenhäger JC., Arntzenius AC. Thyroid Function in Regression of Coronary Atherosclerosis. Arteriosclerosis 1983;3:A465.

9.         Barth JD, Reiber JHC, Hugenholtz PG, Birkenhäger JC, Arntzenius AC. Does thyroid metabolism, independently of lipids, play a role in regression of coronary atherosclerosis J Am Coll Card 1984;3:A550.

10.       Reiber JHC, Kooyman CJ, Serruys PW, Barth JD, Slager CJ, Schuurbiers JCH. Variability in quantitation of coronary arterial segments from cineangiograms. Eur Heart J 1984;5(Suppl 1):A421.

11.       Barth JD, Reiber JHC, Birkenhäger JC, Arntzenius AC, Katen HJ ten, Hugenholtz PG. Sex hormones and cortisol in coronary atherosclerosis. Eur Heart J 1984;5(Suppl 1):A426.

12.        Barth JD, Meester GT. Follow‑up of coronary risk factors in the male patient: one year after myocardial infarction. Eur Heart J 1984;5 (Suppl 1):A1159.

13.       Barth JD, Reiber JHC, Arntzenius AC, Birkenhäger JC, Jansen H, Lubsen J. Does liver lipase activity determine regression or progression of coronary atherosclerosis during dietary intervention ?  Competition Young Investigator Award,(Semi‑Finalist) European Society of Cardiology, Eur Heart J 1984;5(Suppl 1):A1.

14.       Barth JD, Reiber JHC, Birkenhäger JC, Arntzenius AC, Brower RW, Hugenholtz PG. Thyroid metabolism and regression of coronary atherosclerosis. Eur Heart J 1984;5(Supp 1):A1160.

15.       Serruys PW, Deckers JW, Barth JD, Reiber JH, Hugenholtz PG. Long lasting vasodilatory effect of intracoronary administration of SIN 1:A quantitative coronary angiographic study. International Symposium on Molsidomine. Dusseldorf 1984, July 8, p.30 (Abstract).

16.       Barth JD. Pharmacological lipid lowering intervention therapy in the natural course of atherosclerosis. Proceedings Symposium Management of Atherosclerosis, September 1985, Lelystad, The Netherlands.

17.       Arntzenius AC, Kromhout D, Barth JD, Reiber JHC, Bruschke AVG, Buis B, van Gent CM, Kempen‑Voogd N, Strikwerda S, van der Velde EA. The Leiden Diet Intervention Study. Proceedings Symposium Management of Atherosclerosis, September 1985, Lelystad, The Netherlands.

18.       Barth JD, Jansen H, Arntzenius AC, Reiber JHC, Birkenhäger JC. Is liver lipase activity a possible marker of diet inducibility to decelerate atherosclerosis ? Proceedings 7th International Symposium on Atherosclerosis, Melbourne, Australia, October 1985, A243.

19.       Van Durme JP, Lie HK, van Hooghehuyze DCA, Barth JD. et al. A multicenter study: therapeutic efficacy of antiarrhythmic treatment. March 1985, Eindhoven, The Netherlands.

20.       Barth JD, Birkenhäger JC. Sex hormone response patterns to coronary artery bypass surgery.  Arteriosclerosis1985;5:A514.           

21.       Barth JD, Birkenhäger JC. Lipoprotein response patterns during coronary artery bypass surgery. Proceedings Washington Spring Symposium, May 1986.A712.

22.       Arntzenius AC, Barth JD, Kromhout D. Clinical significance of progression and regression of coronary atherosclerosis: The Leiden Intervention Trial. X World Congress of Cardiology, A375. September 13‑19, 1986, Washington, D.C., USA.

23.       Barth JD, Arntzenius AC, Reiber JHC, Jansen H, Kromhout D. Diet and postheparin lipoprotein lipases in regression of coronary atherosclerosis. X World Congress of Cardiology. Finalist Young Investigator Award Competition, A667. September 13‑19, 1986, Washington, D.C.,USA.

24.       Barth JD, Birkenhäger JC. Lipids and glucagon response during coronary bypass surgery. X World Congress of Cardiology. A1829. September 13‑19, 1986, Washington, D.C., USA.

25.       Barth JD, Arntzenius AC, Blankenhorn DH.  Lipoproteins, lipases and thyroid hormones in coronary lesion growth. Clin Res 1987;35:A100.

26.       Barth JD, Blankenhorn DH, Liu LR, Lee JL, Wickham E, Selzer RH. Digitized ultrasound images of different stages of carotid atherosclerosis. Clin Res 1987;36:570A.

27.       Barth JD, Blankenhorn DH, Lai JY, Frieden HJ, Selzer RH. Reliability of digitized carotid ultrasound and angiographic measurements. 8th International Symposium on Atherosclerosis, Rome, Italy, 1988 October 9-13, A52.

28.       Barth JD, Aengevaeren WR, Arends H. Total-and HDL-cholesterol in patients with silent and symptomatic myocardial ischemia. Arteriosclerosis 1988;8:A583.

29.        Barth JD, Van Eijk AL, Kruisbrink OAE, Rasmussen EL, Van der Werf T. Dietary adherence during dissimilar lipid lowering drug therapies in Familiar Hyperlipidemia. Proceedings Second International Symposium on the Management of Atherosclerosis, Rotterdam April 7, 1989. The Netherlands. A93.

30.       Barth JD, Van Eijk AL, Kruisbrink OAE. Lipid lowering dietary assessment in the initiation phase of simvastatin or colestipol treatment in Familiar Hypercholesterolemia. Proceedings 53rd Annual Meeting European Atherosclerosis Society. Vienna, Austria April 20-22 1989. A33.

31.       Barth JD. Regression of Atherosclerosis. Proceedings of the conference on recent advances in cardiac protection and cardiovascular risk management. Monte-Carlo June 11-13, 1989 A2.

32.       Barth JD, Kruisbrink OAE, Van Eijk AL, Van Der Werf T. Simvastatin may interfere with sleep in Familial Hypercholesterolemia. Arteriosclerosis 1989;9:A725

33.       Barth JD, Kruisbrink OAE, Van Eijk AL. Dietary adherence to lipid loering counsilling during simvastatin or colestipol therapy. Xth International Symposium on Drugs Affecting Lipid Metabolism Houston, USA. 1989:A75.

34.       Weerd P. de, Ten Cate FJ, Bernink PJLM, Remme WJ, Barth JD, Enthoven R, Hagen FDM, Holwerda NJ, Klomps HC. An 8-week evaluation of amlodipine and diltiazem in patients with stable exertional angina pectoris. Symposium 24-protection and Control: A New Era of Calcium Antagonists, September 1989.

35.       Barth JD. Regression of Human Coronary Atherosclerosis: What is the mechanism ? In:Prospects and Strategies in Cardiovascular Research. Antwerp, Belgium, February 18-22 1990 p.3.

36.       Barth JD, Kruisbrink OAE, Van Eijk AL. Do cholesterol synthesis inhibitors change dietary adherence ? In: International Symposium on Lipoprotein Metabolism and Lipid Lowering Agents. February 26-March 2 1990, The Hague, The Netherlands. AF-053.(p 28)

37.       Barth JD, Van Den Berg. What is your number ? An assessment of total cholesterol levels in 2 healthy populations. In: International Symposium on Lipoprotein Metabolism and Lipid Lowering Agents. February 26-March 2 1990, The Hague, The Netherlands. AF-069.(p 28)

38.       Kuipers H, Mosterd WL, Barth JD. Angina pectoris: beperking van beweging ?. (Angina; the limiting factor during exercise?). Medicus 1991;291:p.7, 292:p.11 (Dutch).

39.       Barth JD. Cholesterol behandeling : een verpleegkundige taak? (Cholesterol treatment: A nurses task ?) Proceedings 10th Nurses Scientific Council of the Netherlands Heart Foundation May 2, 1991 Utrecht Netherlands. pp 12-13.

40.       Barth JD, Meester GT, Meijler FL, REGRESS Research Group. "REGRESS": A trial to assess the lipid lowering effects of pravastatin in 'normocholesterolemic' men with myocardial ischemia. JACC 1991;17:69A.

41.       Barth JD, Jansen H, Birkenhäger JC. Lipoproteins and Lipases in Normocholesterolemic Men with Symptomatic Coronary Atherosclerosis; The REGRESS Trial. 9th International Symposium on Atherosclerosis, October 6-11, 1991, Rosemont, U.S.A. p.21.

42.       Barth JD, Jansen H, Boerma GJ, Zonjee MMB, Sartorius OEH. SymptomaticCoronary Heart Disease and Follow-up Intervention Mode: The REGRESS Trial. 9th International Symposium on Atherosclerosis, October 6-11, 1991, Rosemont, U.S.A. p.21.

43.       Barth JD, Jansen H, Boerma GJ, Zonjee MMB, Sartorius OEH, Meijler FL, Meester GT. PTCA, CABG, or Drug Therapy in Symptomatic Coronary Heart Disease: The REGRESS Trial.  9th International Symposium on Atherosclerosis, October 6-11, 1991, Rosemont, U.S.A. p.262.

44.       Barth JD, Janse LC, Zonjee MM, Rappard F.van. Dietary Assessment in Symptomatic Normocholesterolemic Men Who Were Assigned to Either PTCA, CABG or Antianginal Therapy. Arteriosclerosis and Thrombosis 1991;11:1614a.

45.       Jansen H, Barth JD, Zonjee MM, Birkenhäger JC. Lipoprotein Fractions in Normocholesterolemic Men With Symptomatic Coronary Heart Disease. Arteriosclerosis and Thrombosis 1991;11:1461a.

46.       Barth JD, de Heide L,de Groot E,Van Swijndrecht Alexander, Bond G,Selzer RH,Jansen H,van Urk H,Ackerstaff R, Birkenhager JC. Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands (The DAPHNE study) June 12, 1992, International Hypertension Conference Meeting, Toledo, Spain:32-34.

47.       Barth JD, Heide L de, Swijndregt A van. Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands (the DAPHNE study). Focus on Ultrasound Assessment Proceedings of symposium 'The atherosclerotic process in the hypertensive patient: does drug selection make a difference?'. , World Congres on Stroke, Washington DC September 1992, 12-14.

48.       Barth JD. Assessment of possibilities to detect change of atherosclerosis in Proceedings of Third International Symposium on the Management of Atherosclerosis, Rotterdam The Netherlands. ISBN 90-9005582-7. Vianen, Netherlands p.37.

49.       Barth JD. Methods to Assess Atherosclerosis Change: Clinical Implications. Proceedings Symposium Coronary Atherosclerosis Prevention to Regression Japan Circulation Society Scientific Meeting,  March 24, 1993 Tokyo pp 5-6.

50.       Barth JD, Seccombe D, Johnson F. Management of Cardiac Risk Factors: Proceedings Symposium on Cardiac Wellness-Prevention and Rehabilitation. Vancouver, BC, Canada, April 16, 1993 pp 24-25.

51.       Barth JD, Frohlich J. Behavioral Modification of Coronary Risk Factors: A New Approach to Hypertension and Hyperlipidemia. Proceedings Heart and Stroke Foundation Scientific Meeting February 18, 1993 Vancouver, BC, Canada pp 18-19.

52.       Barth JD. To regress or not to progress- that is the question. Lipid Update I, Stratford-upon-Avon U.K. May 24-26, 1993 abstract 5.2, p 24.

53.       Barth JD. Pharmacological prevention and regression of coronary disease. Lipids, Life style and cardiac rehabilitation. Abstract pp 14-15. September 25-26, 1993 Whistler, Canada

54.       Kennedy-Symonds H, Barth JD, Kerr CR. Psychological stress testing relevant to noncardiac chest pain and esophageal motor disorders. Can J Cardiol 1993;9 (suppl E):70E # 22.

55.       Barth JD. Tratamieto hipolipemiante:regresion de la placa de ateroma y reduccion de los eventos secundarios.Proceedings IV Simposio Internacional sobre Lipidos y Aterosclerosis:1994 pp 54-56 

56.       Ray SG, Penn IM, Ricci DR, Barth JD, Mancini GBJ, Buller CE, O'Neill B, Foster Ch, Almond D. Mechanism of benefit of stenting in failed PTCA. Final results from the trial of angioplasty and stents in Canada. JACC 1995;156A

57.       Barth JD Early detection and prevention of atherosclerosis in the carotid artery. V International Symposium on Non-invasive cardiovascular testing. Israel 1995

58.       Dwyer KM, Selzer RH, Barth JD, Sun P, Nicholson L,  Dwyer JH Quercetin-rich foods and carotid atherosclerosis 1996 VII Biennial Meeting International Society for Free Radical Research Barcelona Spain A 5.172

59.       Barth JD, Rupich R, Zonjee M, O'Donnel T. Quantitative Intima Media Thickness Measurements of the carotid artery in women with and without a history of hormone replacement. American Society of Bone and Mineral Research 1997 Cincinnati AF506

60.       Dwyer JH, Sun P, Dwyer KM, Barth J. D. Selzer RH. Carotid intima media thickness and blood pressure in women and men: The Los Angeles Atherosclerosis Study American Heart Association Scientific Sessions Orlando 1997 A 1540.

61.       Dwyer KM, Mellett L, Sun P, Selzer RH, Barth JD, Dwyer JH.Carotid wall thickness and years since bilateral oopherectomy:the Los Angeles Atherosclerosis Study.  American Heart Association Scientific Sessions Orlando 1997 A 2268.

62.       Barth JD, Zonjee M, Shircore A. Two new non-invasive techniques to assess cardiovascular disease progression. World Foundation For Medical Studies in Female Health Scientific Sessions Miami 1997 A 48.

63.       Barth JD Shircore A, Zonjee M Quantitative Assessment of Intima Media Thickness of the common carotid artery in women with and without hormone replacement. Abstract #54 Vascular Biology 1998 American Heart Association San Francisco 1998.

64.       Barth JD, Shircore A, Zonjee M. Carotid Bifurcation plaques exhibit a different cardiovascular risk factor profile than Intima Media Thickness of the common carotid artery. Abstract #55 Vascular Biology 1998 American Heart Association San Francisco 1998.

65.       Barth JD, Zonjee M, Rupich R.Quantitative assessment of intima media thickness in Hormone replacement therapy Amsterdam Menopause Symposium 1998 Abstract # 33

66.       Barth JD. Hormones and Heart Disease: What do they have in common? The 1998 Asia Pacific Conference on Bone Health March 1998 Hawaii AClinic A5

67.       Barth JD on behalf of the DUC. Little difference found in lipid lowering effects of different compounds in a preferred provider situation. International Congress on Vascular Disease Prevention Glasgow Scotland 1998 Abstract 11.

68.        Barth JD, Zhang L, Rupich R, Zonjee M. Quantitative carotid intima media thickness: A novel, reproducible, and non-invasive technique that may prove useful for assessing early atherosclerosis. Abstract A4 Enzymes, Receptors and Drugs in Obesity and Atherosclerosis. Toronto, Canada, 1998.

69.        Barth JD; Patient Compliance and Medications. SHARP 10 th Scientific Meeting, Perth, Scotland, November 27, 1998.

70.        Barth JD, Haddal A, Zhang L, Frierson C, Zonjee M, Silverman S. Endothelial Function in Smoking Young Adults AIM 98 Los Angeles, December 10, 1998, Pages 40-41.

71.        Barth JD, Zhang Ling, Zonjee M. A picture tells a thousand words. A personalized picture enhances a patient's compliance. AHA meeting on Patient Compliance, April 29-30, 1999, Waltham Mass. Poster # 9. 

72.       Barth JD, Taylor-Munoz E, Zhang E, Zonjee M A personalized image promotes patients’ adherence to lifestyle recommendations 16 Asian Conference on Occupational Health November 1999 Cebu City, Philippines. Proceedings, FP1, 48.

73..      Barth JD, Sanchez A, Zhang L, Zonjee M.   High School students’ vascular wall is associated with the heart disease risk factors for adults.  Scientific Sessions of the American College of cardiology, March 2000, Anaheim CA A 22. 

74.       Sanchez A, Barth JD, Zhang L.  Diet and its relation to early atherosclerosis in teenagers. Scientific Sessions of the American College of Cardiology, March 2000, Anaheim CA A13.

75.       Sanchez A, Barth JD, Zhang L. Standards needed for intima media thickness of the carotid artery in teenagers to study risk factors related to nascent atherosclerosis. AHA Atherosclerosis in the Young meeting La Jolla March 2000.A 6.

Letters to the Editor:

1.         Barth JD, Arntzenius AC, Kromhout D. Follow‑up on Leiden Trial. N Engl J Med 1987;316:881‑882 (Letter to the Editor).

2.         Barth JD. Regression of atherosclerosis (Editorial). Can J Cardiol 1992;8: 911-912.

3.         Barth JD. Treatment of/and screening for hyperlipidemia N Engl J Med 1993;329:1125 (letter to the editor).

4.         Hodis HN, Mack WJ, Barth JD. Carotid intima-media thickness as a surrogate end       point for coronary artery disease. Circulation 1996;94:2311-2

Chapters:

1.         Verschoor L, Jansen H, Zonneveld AJ, Barth JD, Birkenhger JC. High‑density Lipoprotein cholesterol and testosterone. Lipoprotein Metabolism and Endocrine Regulation. Hessel LW. and Krans HMJ editors. Elsevier/North‑Holland Biomedical Press, Amsterdam, 1979;99‑106.

2.         Arntzenius AC, Barth JD, Bruschke AVG, Buis B, Gent CM van, Houtsmuller UMT, Kempen‑Voogd N, Kromhout D, Reiber JHC, Strikwerda S, van der Velde EA, Wezel LA van. Preliminary report on coronary lesions and serum lipids before and after two years dietary intervention in 22 patients. Proceedings 6th International Symposium on Atherosclerosis. Schettler FG, Gotto AM, Middelhoff G, Habernicht AJR, Jurutka KR. Editors. Springer Berlin, 1982;pp 187‑196.

3.      Arntzenius AC, Kromhout D, Barth JD. The Leiden Intervention Trial.  Clinical significance of lesion growth in two years. Proceedings 7th International Symposium on Atherosclerosis, Melbourne, Australia, 1986 Elsevier Science Publishers B.V.(Biomedical Division) Atherosclerosis VII, Fidge NH, Nestel PJ. Editors. pp. 79‑83.

4.         Jansen H, Laird‑Meeter K, Barth JD, Baggen MGA, Van Agen B, Van Es GA, Hugenholtz PG, Birkenhäger JC. The effect of Prazosin and Propranolol treatment on plasma lipoproteins and postherparin plasma lipase activities.  Proceedings Washington Spring Symposium, May 1986 ( Proc.).

5.         Barth JD, Jansen H, Arntzenius AC, Birkenhäger JC. Quantitative Coronary Angiography in a Lipid Intervention Study. The Leiden Intervention Trial. In: Quantitative Coronary and Left Ventricular Cineangiography. Martinus‑Nyhoff Publishers, Amsterdam. Reiber JHC, Serruys PW, Slager CJ. 1986 Editors. pp. 408‑425.(Chapter XXII).

6.         Barth JD, (Issue Editor), De Leeuw PW, (Series Editor) Hypertension Cholesterol and Atherosclerosis Part 2 Modern Survey on Hypertension.  Excerpta Medica 1986 Amsterdam, The Netherlands.

7.         Barth JD. Pathophysiology of treatment of lipid disorders.In: Atherosclerose en Coronaire insufficientie (Dutch). Editors van der Werf T, Arntzenius AC. Publisher Bunge, Utrecht, The Netherlands 1988 pp 181-196.

8.         Barth JD, Arntzenius AC. Regression of Atherosclerosis in humans: the evidence and the role of changes in cholesterol and HDL-cholesterol. In: Proceedings 2nd International Symposium on the Management of Atherosclerosis. Arntzenius AC., Birkenhager JC., Barth JD. (Eds.) Boerhaave Committee in Postgraduate Education Leiden Netherlands 1989:p 27-52.

9.         Arntzenius AC, Kromhout D, Barth JD. Measured coronary lesion change in relation to blood levels in the Leiden Intervention Trial and a view of the atherosclerotic process. In: Pathobiology of the human atherosclerotic plaque, Glagov S., Newman WP., Schaffer SA. (Eds.) Springer Verlag New York 1990 p.551-570.

10.       Barth JD. Lipid Management: Pravastatin and the Differential Pharmacology of HMG-Co A Reductase Inhibitors, Wood C. Editor, Royal Society of Medicine Services 1990 Round Table Series 16 p.32-40.

11.       Reiber JHC, Serruys PW, Barth JD. 'Quantitative Coronary Angiography' in Cardiac Imaging: Principles and Practice. Eds. Marcus ML, Skorton DL, Schelbert HR, Wolf GL. W.B.Saunders Company, Philadelphia USA 1991; pp 211-280.

12.       Barth JD. Advances in the treatment of hypercholesterolemia. Low-dose monotherapy and combination therapy with colestipol.  1992 Nice France Monograph

13.       Barth JD in Betteridge DJ: Dyslipidaemia Chapter 9: Lipoproteins and the progression/regression of atherosclerosis 1995;7:849-867.

14.       Barth JD, Hodis NH. The Atherosclerosis Regression Trials - Is It All Good News ? in Lipids: Current Perspectives chapter 15 pp.245-261 Martin Dunitz London UK eds D. John Betteridge.

15.       Barth JD, Mancini GBJ. Chapter 123 "Pravastatin" Drugs and Pharmacotherapy 1996 eds Messerli F, Saunders 

16.       Barth JD Primary Preventive and Secondary prevention: one disease, two different management strategies? Chapter 1 in Difficult Cardiology III Ed Graham Jackson Martin Dunitz 1997  1-27.      

Books:

1.         Proceedings of the Second International Symposium on the Management of Atherosclerosis Boerhaave Committee of Postgraduate Medical Education, Leiden University and The Postgraduate Committee of Medical Education of Erasmus University Rotterdam the Netherlands.

2.         Proceedings of the Third International Symposium on the Management of Atherosclerosis. Vianen, The Netherlands, Rotterdam, 1992, November 6 and 7.

MeSuá Dermocosmetic Spa^®
1900 Brickell Avenue, Miami, Florida 33129
Call Toll Free: 1 877 77 MESUA (1-877-776-3782)
drmesua@mesua.com